Skip to main content

FloLipid Side Effects

Generic name: simvastatin

Medically reviewed by Last updated on Jun 11, 2022.

Note: This document contains side effect information about simvastatin. Some of the dosage forms listed on this page may not apply to the brand name FloLipid.

For the Consumer

Applies to simvastatin: oral suspension, oral tablet

Side effects requiring immediate medical attention

Along with its needed effects, simvastatin (the active ingredient contained in FloLipid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking simvastatin:

More common

Less common

  • Bladder pain
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • chills
  • cough
  • dark-colored urine
  • difficult, burning, or painful urination
  • difficulty with breathing
  • difficulty with moving
  • dry mouth
  • ear congestion
  • fever
  • flushed, dry skin
  • frequent urge to urinate
  • fruit-like breath odor
  • headache
  • increased hunger
  • increased thirst
  • increased urination
  • joint pain
  • loss of consciousness
  • lower back or side pain
  • muscle cramps, spasms, stiffness, pain, tenderness, wasting, or weakness
  • nausea
  • runny or stuffy nose
  • sneezing
  • sore throat
  • stomachache
  • sweating
  • swelling
  • swollen joints
  • trouble breathing
  • unexplained weight loss
  • unusual tiredness or weakness
  • vomiting

Incidence not known

  • Blistering, peeling, or loosening of the skin
  • bloating
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest tightness
  • constipation
  • diarrhea
  • difficulty with swallowing
  • general tiredness and weakness
  • indigestion
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • loss of appetite
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • pale skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • skin rash, hives, or itching
  • sores, ulcers, or white spots in the mouth or on the lips
  • unusual bleeding or bruising
  • upper right abdominal or stomach pain
  • weakness in the arms, hands, legs, or feet
  • yellow eyes or skin

Side effects not requiring immediate medical attention

Some side effects of simvastatin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Acid or sour stomach
  • belching
  • burning feeling in the chest or stomach
  • dizziness or lightheadedness
  • excess air or gas in the stomach or intestines
  • feeling of constant movement of self or surroundings
  • full feeling
  • heartburn
  • lack or loss of strength
  • pain or tenderness around the eyes and cheekbones
  • passing gas
  • sensation of spinning
  • skin rash, encrusted, scaly, and oozing
  • stomach discomfort, upset, or pain
  • tenderness in the stomach area
  • trouble sleeping

Incidence not known

  • Being forgetful
  • depression
  • discoloration of the skin
  • hair loss or thinning of the hair
  • inability to have or keep an erection
  • loss in sexual ability, desire, drive, or performance

For Healthcare Professionals

Applies to simvastatin: oral suspension, oral tablet


The more commonly reported adverse effects have included upper respiratory infection, headache, abdominal pain, constipation, and nausea.[Ref]


Common (1% to 10%): Myalgia

Uncommon (0.1% to 1%): Myopathy

Frequency not reported: Elevations in creatine kinase, myopathy, dermatomyositis, arthralgia, tendon rupture

Postmarketing reports: Muscle cramps, myalgia, rhabdomyolysis[Ref]

This drug causes dose-related myopathy which, in rare cases maybe severe and sometimes take the form of rhabdomyolysis with or without renal failure secondary to myoglobinuria; rarely fatalities have occurred. The incidence of myopathy with the 80 mg dose has been reported as disproportionately higher than that observed at lower doses and the risk of myopathy with simvastatin 80 mg/day is greater compared with other statins with similar or greater LDL-C lowering efficacy.[Ref]


Persistent elevations in transaminases of up to 3 times the upper limit of normal (3xULN) have been reported in 1% of patients. With therapy discontinuation or interruption, transaminase levels generally returned to pretreatment levels. There have been rare postmarketing reports of hepatic failure.[Ref]

Common (1% to 10%): Elevations in liver function tests

Frequency not reported: Hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty changes in the liver, cirrhosis, hepatic failure, fulminant hepatic necrosis

Postmarketing reports: Hepatic failure, hepatitis, jaundice[Ref]


Common (1% to 10%): Constipation, nausea, flatulence, diarrhea, dyspepsia, abdominal pain, gastritis

Frequency not reported: Anorexia

Postmarketing reports: Pancreatitis, vomiting[Ref]


Frequency not reported: Hemolytic anemia, thrombocytopenia, leucopenia, thrombotic thrombocytopenic purpura (TTP)

Postmarketing reports: Anemia[Ref]

Nervous system

Common (1% to 10%): Headache, vertigo

Frequency not reported: Cognitive impairment, cranial nerve dysfunction, tremor, vertigo, memory loss, paraesthesias, peripheral neuropathy, peripheral nerve palsy

Postmarketing reports: Dizziness, paresthesia, peripheral neuropathy, cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion)[Ref]


Frequency not reported: Myoglobinuria, acute renal failure secondary to rhabdomyolysis[Ref]


Common (1% to 10%): Angina, edema, atrial fibrillation[Ref]


Common (1% to 10%): Eczema

Frequency not reported: Pruritic rash, erythema multiform including Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity, purpura

Postmarketing reports: Pruritus, alopecia, a variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails)[Ref]


Frequency not reported: Anaphylaxis, angioedema, urticaria, fever, chills, flushing, malaise, dyspnea

Postmarketing reports: Hypersensitivity syndrome which has included some of the follow features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme including Stevens-Johnson syndrome[Ref]


Postmarketing reports: Immune-mediated necrotizing myopathy[Ref]


Frequency not reported: Progression of cataracts, ophthalmoplegia[Ref]


Common (1%to 10%): Insomnia

Postmarketing reports: Depression[Ref]


Common (1% to 10%): Urinary tract infection

Frequency not reported: Impotence, testicular pain, proteinuria

Postmarketing reports: Erectile dysfunction[Ref]


Frequency not reported: Tumor growth, liver, thyroid, lung adenomas, carcinomas[Ref]


Common (1% to 10%): Diabetes mellitus

Frequency not reported: HbA1c and fasting serum glucose levels elevations


Common (1% to 10%): Respiratory tract infection, bronchitis, sinusitis

Postmarketing reports: Interstitial lung disease


Frequency not reported: Asthenia

Frequently asked questions


1. Lossos IS, Halkin A, Mevorach D "HMG-CoA reductase inhibitor-induced impotence." Ann Pharmacother 30 (1996): 192

2. Katznelson S "Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors." Transplant Proc 31 (1999): s22-4

3. Katznelson S "Effect of HMG-CoA reductase inhibitors on chronic allograft rejection." Kidney Int 56 (1999): s117-21

4. Walker JF "Simvastatin: the clinical profile." Am J Med 87 (1989): s44-6

5. Simons LA "Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators." Clin Cardiol 16 (1993): 317-22

6. Bilheimer DW "Long-term clinical tolerance of lovastatin and simvastatin." Cardiology 77 (1990): 58-65

7. "Product Information. Zocor (simvastatin)." Merck & Company Inc (2001):

8. Abadia R, Agnus D, Chariot P, Charpentier C, Gherardi RK, Danan C "Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome." Am J Med 94 (1993): 109-10

9. McDonagh J, Winocour P, Walker DJ "Musculoskeletal manifestations during simvastatin therapy." Br J Rheumatol 32 (1993): 647-8

10. Mctavish D, Plosker GL "Simvastatin - a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia." Drugs 50 (1995): 334-63

11. Cook TJ, Miettinen T, Haghfelt T, Pyorala K, Thorgeirsso, Kjekshus J, Berg K, Faergeman O, Musliner TA, Olsson AG, Pedersen TR "Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study." Arch Intern Med 156 (1996): 2085-92

12. Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ, Vanpuijenbroek EP "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996): 403-4

13. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996): 403-4

14. Alvarez JM, Goldstein J, Rawdanowiz TJ "Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin." J Thorac Cardiovasc Surg 116 (1998): 654-5

15. Possidente CJ, Weise WJ "Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient." Am J Med 108 (2000): 351-2

16. Meier CR, Schlegel B, Schlienger RG, Jick H, Kraenzlin ME "HMG-CoA reductase inhibitors and the risk of fractures." JAMA 283 (2000): 3205-10

17. Morris IM, Khattak FH, Branford WA "Simvastatin-associated dermatomyositis." Br J Rheumatol 33 (1994): 199

18. ChoquetKastylevsky G, Kanitakis J, Claudy A, Descotes J, Dumas V, Faure M "Eosinophilic fasciitis and simvastatin." Arch Intern Med 161 (2001): 1456-7

19. Chiu RW, Chow CC, Chan IH, Lam CW, Chan MH, Mak TW "Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia." J Clin Endocrinol Metab 86 (2001): 4556-9

20. Peces R, Pobes A "Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem." Nephron 89 (2001): 117-8

21. Federman DG, Walters AB, Hussain F "Fatal rhabdomyolysis caused by lipid-lowering therapy." South Med J 94 (2001): 1023-6

22. Wilson JP, Omar MA "FDA adverse event reports on statin-associated rhabdomyolysis." Ann Pharmacother 36 (2002): 288-95

23. Melton LB, Ogu CC, Sills MN, Maxa JL, Limanni A "Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole." Ann Pharmacother 36 (2002): 820-3

24. "Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels." Ann Intern Med 137 (2002): I45

25. Grundy SM "Can statins cause chronic low-grade myopathy?" Ann Intern Med 137 (2002): 617-8

26. Sinzinger H, Wolfram R, Peskar BA "Muscular side effects of statins." J Cardiovasc Pharmacol 40 (2002): 163-71

27. Haller DG, O'Dwyer PJ, Itakura H, Vaughn D "Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer." J Urol 169 (2003): 613

28. Diaczok BJ, Shali R "Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease." South Med J 96 (2003): 318-20

29. Graham DJ, Shatin D, Staffa JA, et al. "Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs." JAMA 292 (2004): 2585-90

30. Gonyeau MJ "Statins and osteoporosis: a clinical review." Pharmacotherapy 25 (2005): 228-43

31. Finsterer J, Zuntner G "Rhabdomyolysis from Simvastatin triggered by infection and muscle exertion." South Med J 98 (2005): 827-9

32. Mukhtar RY, Reckless JP "Statin-induced myositis: a commonly encountered or rare side effect?" Curr Opin Lipidol 16 (2005): 640-7

33. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

34. Arora R, Liebo M, Maldonado F "Statin-induced myopathy: the two faces of Janus." J Cardiovasc Pharmacol Ther 11 (2006): 105-12

35. Andrews B, Ramdass MJ, Singh G "Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism." Postgrad Med J 83 (2007): 152-3

36. Andersson KS, Molden E "Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients." Pharmacotherapy 27 (2007): 603-7

37. MacDonald JL, Mauro VF "Simvastatin: a review of its pharmacology and clinical use." DICP 25 (1991): 257-64

38. Bataille L, Horsmans Y, Nakad A, Sempoux C, Hamoir V "Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin." Lancet 353 (1999): 1763-4

39. Cerf M, Chagnon JP "Simvastatin-induced protein-losing enteropathy." Am J Gastroenterol 87 (1992): 257

40. Johnson JL, Loomis IB "A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis." Pharmacotherapy 26 (2006): 414-22

41. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA "Australian Adverse Drug Reactions Bulletin." (2007):

42. Pavord S, Sundram F, Kennedy B, Roberts P "Thrombotic thrombocytopenic purpura associated with statin treatment." Postgrad Med J 80 (2004): 551-2

43. Halpern JP, Mcleod JG, Peiris O, Pollard JD, Rohan A, Phan T "Peripheral neuropathy associated with simvastatin." J Neurol Neurosurg Psychiatry 58 (1995): 625-8

44. Orsi A, Sherman O, Woldeselassie "Simvastatin-associated memory loss." Pharmacotherapy 21 (2001): 767-9

45. Andersen M, Hallas J, Garcia Rodriguez LA, Gaist D, Jeppesen U, Sindrup SH "Statins and risk of polyneuropathy: a case-control study." Neurology 58 (2002): 1333-7

46. Muldoon MF, Flory JD, Manuck SB, Ryan CM, Sereika SM "Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults." Am J Med 117 (2004): 823-9

47. Morales K, Wittink M, Datto C, et al. "Simvastatin causes changes in affective processes in elderly volunteers." J Am Geriatr Soc 54 (2006): 70-6

48. Gregoor PJ "Atorvastatin may cause nightmares." BMJ 332 (2006): 950

49. Sessa A, Polimeni G, Salvo F, Galatti L, Romani M, Spina E "Short-term memory loss associated with rosuvastatin." Pharmacotherapy 26 (2006): 1190-2

50. Potter JF, Padala KP, Padala PR "Simvastatin-induced decline in cognition." Ann Pharmacother 40 (2006): 1880-3

51. Miettinen T, Haghfelt T, Pyorala K, Thorgeirsson G, Kjekshus J, Wilhelmsen L, Berg K, Wedel, Faergeman O, Olsson AG, Pedersen TR "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)." Lancet 344 (1994): 1383-9

52. Feldmann R, Saurat JH, Mainetti C "Skin lesions due to treatment with simvastatin (Zocor)." Dermatology 186 (1993): 272

53. Burg G, Krasovec M, Elsner P "Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors." Dermatology 186 (1993): 248-52

54. Bannwarth B, Papapietro PM, Miremont G "Lupuslike syndrome associated with simvastatin." Arch Intern Med 152 (1992): 1093

55. Danoff D, Rabinovitch MA, Rudski L "Systemic immune reactions to HMG-CoA reductase inhibitors - Report of 4 cases and review of the literature." Medicine 77 (1998): 378-83

56. Duits N, Bos FM "Depressive symptoms and cholesterol-lowering drugs." Lancet 341 (1993): 114

57. Linnebur SA, Hiatt WH "Probable Statin-Induced Testicular Pain (January)." Ann Pharmacother (2007):

58. Newman TB, Hulley SB "Carcinogenicity of lipid-lowering drugs." JAMA 275 (1996): 55-60

59. LeLorier J, Bjerre LM "Do statins cause cancer? A meta-analysis of large randomized clinical trials." Am J Med 110 (2001): 716-23

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.